9,923 Results

Phase III trial of Imbruvica + chemo fails to meet endpoint in pancreatic cancer.- AbbVie

 Added 2 days ago

AbbVie announced an update on the Phase III RESOLVE trial (PCYC-1137) of Imbruvica (ibrutinib) in combination with chemotherapy agents nab-paclitaxel...

UK NICE recommends use of Verzenios in breast cancer.- Eli Lilly

 Added 2 days ago

The UK's NICE has recommended the use of Verzenios (abemaciclib), from Eli Lilly, for locally advanced or metastatic forms of...

FDA Advisory Committee recommends Evenity to treat osteoporosis- Amgen + UCB

 Added 2 days ago

Amgen and UCB announced strong support from the FDA Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval...

Phase III REACH-2 study of Cyramza to treat AFP-High liver cancer is published in The Lancet Oncology. - Eli Lilly

 Added 2 days ago

Eli Lilly and Company announced that results from the global Phase III REACH-2 study of Cyramza (ramucirumab) as a single...

NICE recommends Bravtovi + Mektovi combination in melanoma.- Pierre Fabre + Array Biopharma

 Added 3 days ago

The UK National Institute for Health and Care Excellence (NICE) has recommended Bravtovi (encorafenib) plus Mektovi (binimetinib) from Pierre Fabre...

Phase III TAGS data for Lonsurf consistent with earlier studies in gastric cancer.- Taiho Oncology + Servier

 Added 3 days ago

Taiho Oncology and Servier announced that the safety and efficacy in patients with gastrectomy from the global Phase III TAGS...

NICE recommends Venclyxto plus Rituxan in chronic lymphocytic leukaemia.- AbbVie + Genentech/Roche

 Added 3 days ago

The National Institute for Health and Care Excellence (NICE) has recommended Venclyxto (venetoclax) with Rituxan (rituximab), from AbbVie + Genentech/Roche,...

Complete Response Letter for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer . Immunomedics

 Added 3 days ago

Immunomedics, Inc. announced it has received a Complete Response Letter (CRL) from the FDA for the Biologics License Application (BLA)...

Three post approval studies of sutureless Perceval Aortic Heart Valve.-LivaNova PLC

 Added 3 days ago

LivaNova PLC announced the publication of three separate studies highlighting the unique performance of its sutureless aortic valve, Perceval. The...

FDA advisory committee voted 8:8 on the overall benefits of Zynquista to treat type 1 diabetes. Sanofi + Lexicon

 Added 3 days ago

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted eight to eight on the question of whether the...

Load more